Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 30
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
10/24/2008
 
First Published:
10/1/2001
1.
Phase III Randomized Study of Response-Based Chemotherapy With Doxorubicin, Bleomycin, Vincristine, Etoposide, Prednisone, and Cyclophosphamide With or Without Dexamethasone, Etoposide, Cytarabine, Cisplatin, and/or Radiotherapy in Children With Newly Diagnosed Intermediate-Risk Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
21 and under
NCI
COG-AHOD0031
NCT00025259, AHOD0031
Last Modified:
5/23/2007
2.
Phase I/II Study of Epstein Barr Virus Specific Cytotoxic T Lymphocytes from a Normal HLA-Compatible Donor in the Treatment of Patients With Epstein Barr Virus Associated Lymphomas and Other Lymphoproliferative Diseases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
Not specified
Other
MSKCC-95024
NCI-V95-0685, NCT00002663
Last Modified:
9/29/2008
 
First Published:
2/26/2008
3.
Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
70 and under
Other
BCM-H-19386
BCM-FAB, H 19386, NCT00625144
4.
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
0 to 55
Other
8717
NCT00673114
5.
A Multi-Center Phase I Study of AP23573 in Pediatric Patients With Advanced Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
1 to 17
Other
SUN08-01
NCT00704054
Last Modified:
10/22/2008
 
First Published:
5/28/2004
6.
Phase II Study of Umbilical Cord Blood as a Source of Hematopoietic Stem Cells for Transplantation in Children With Malignant or Non-Malignant Diseases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
21 and under
Other
PSCI-2003-232
NCT00084695
Last Modified:
5/28/2008
 
First Published:
3/17/2006
7.
Phase II Study of Nonmyeloablative Conditioning Regimen Comprising Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Umbilical Cord Blood Transplantation and Post-Transplant Immunosuppression Comprising Cyclosporine and Mycophenolate Mofetil in Patients With Hematologic Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Under 70
NCI
UMN-2005LS036
UMN-MT-2005-02, UMN-0507M70121, NCT00305682
8.
Therapy for Pediatric Hodgkin Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
21 and under
Other
HOD99
NCT00145600
Last Modified:
1/4/2008
 
First Published:
6/22/2006
9.
Phase II Study of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Non-Hodgkin's or Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Under 70
NCI
UMN-2005LS048
UMN-0508M72589, UMN-MT2004-24, NCT00345865
10.
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Natural history/Epidemiology, Treatment
Active
21 and under
Other
HOD05
NCT00352027
Select All on One Page
1
2
3
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute